203 related articles for article (PubMed ID: 12707149)
1. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury.
Neff TA; Doelberg M; Jungheinrich C; Sauerland A; Spahn DR; Stocker R
Anesth Analg; 2003 May; 96(5):1453-1459. PubMed ID: 12707149
[TBL] [Abstract][Full Text] [Related]
2. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses.
Kasper SM; Meinert P; Kampe S; Görg C; Geisen C; Mehlhorn U; Diefenbach C
Anesthesiology; 2003 Jul; 99(1):42-7. PubMed ID: 12826840
[TBL] [Abstract][Full Text] [Related]
3. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery.
Gallandat Huet RC; Siemons AW; Baus D; van Rooyen-Butijn WT; Haagenaars JA; van Oeveren W; Bepperling F
Can J Anaesth; 2000 Dec; 47(12):1207-15. PubMed ID: 11132743
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment.
Jungheinrich C; Scharpf R; Wargenau M; Bepperling F; Baron JF
Anesth Analg; 2002 Sep; 95(3):544-51, table of contents. PubMed ID: 12198032
[TBL] [Abstract][Full Text] [Related]
5. Penetration of intravenous hydroxyethyl starch into the cerebrospinal fluid in patients with impaired blood-brain barrier function.
Dieterich HJ; Reutershan J; Felbinger TW; Eltzschig HK
Anesth Analg; 2003 Apr; 96(4):1150-1154. PubMed ID: 12651675
[TBL] [Abstract][Full Text] [Related]
6. Influence of different volume therapies on platelet function in the critically ill.
Boldt J; Müller M; Heesen M; Heyn O; Hempelmann G
Intensive Care Med; 1996 Oct; 22(10):1075-81. PubMed ID: 8923073
[TBL] [Abstract][Full Text] [Related]
7. Large-dose administration of 6% hydroxyethyl starch 200/0.5 total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin.
Vogt NH; Bothner U; Lerch G; Lindner KH; Georgieff M
Anesth Analg; 1996 Aug; 83(2):262-8. PubMed ID: 8694303
[TBL] [Abstract][Full Text] [Related]
8. A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch.
Strauss RG; Pennell BJ; Stump DC
Transfusion; 2002 Jan; 42(1):27-36. PubMed ID: 11896309
[TBL] [Abstract][Full Text] [Related]
9. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5.
Langeron O; Doelberg M; Ang ET; Bonnet F; Capdevila X; Coriat P
Anesth Analg; 2001 Apr; 92(4):855-62. PubMed ID: 11273914
[TBL] [Abstract][Full Text] [Related]
10. Cardiopulmonary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy.
Boldt J; Suttner S; Brosch C; Lehmann A; Röhm K; Mengistu A
Anesth Analg; 2009 Dec; 109(6):1752-62. PubMed ID: 19923501
[TBL] [Abstract][Full Text] [Related]
11. Volume therapy in the critically ill: is there a difference?
Boldt J; Müller M; Mentges D; Papsdorf M; Hempelmann G
Intensive Care Med; 1998 Jan; 24(1):28-36. PubMed ID: 9503219
[TBL] [Abstract][Full Text] [Related]
12. Plasma substitution effects of a new hydroxyethyl starch HES 130/0.4 compared with HES 200/0.5 during and after extended acute normovolaemic haemodilution.
Ickx BE; Bepperling F; Melot C; Schulman C; Van der Linden PJ
Br J Anaesth; 2003 Aug; 91(2):196-202. PubMed ID: 12878617
[TBL] [Abstract][Full Text] [Related]
13. Highly substituted hydroxyethyl starch (HES200/0.62) leads to Type-I von Willebrand syndrome after repeated administration.
Treib J; Haass A; Pindur G; Miyachita C; Grauer MT; Jung F; Wenzel E; Schimrigk K
Haemostasis; 1996; 26(4):210-3. PubMed ID: 8872132
[TBL] [Abstract][Full Text] [Related]
14. Is the use of hydroxyethyl starch as priming solution during cardiac surgery advisable? A randomized, single-center trial.
Svendsen ØS; Farstad M; Mongstad A; Haaverstad R; Husby P; Kvalheim VL
Perfusion; 2018 Sep; 33(6):483-489. PubMed ID: 29199540
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of acetyl starch as a plasma volume expander in patients undergoing elective surgery.
Behne M; Thomas H; Bremerich DH; Lischke V; Asskali F; Förster H
Anesth Analg; 1998 Apr; 86(4):856-60. PubMed ID: 9539615
[TBL] [Abstract][Full Text] [Related]
16. Effects of Hydroxyethyl Starch 130/0.4 on Serum Creatinine Concentration and Development of Acute Kidney Injury in Nonazotemic Cats.
Sigrist NE; Kälin N; Dreyfus A
J Vet Intern Med; 2017 Nov; 31(6):1749-1756. PubMed ID: 28862347
[TBL] [Abstract][Full Text] [Related]
17. The effect of 6% hydroxyethyl starch 130/0.4 on renal function, arterial blood pressure, and vasoactive hormones during radical prostatectomy: a randomized controlled trial.
Kancir ASP; Johansen JK; Ekeloef NP; Pedersen EB
Anesth Analg; 2015 Mar; 120(3):608-618. PubMed ID: 25627076
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the safety and tolerance of 6% hydroxyethyl starch (200/0.5) solution: a randomized, controlled epidemiology study.
Bothner U; Georgieff M; Vogt NH
Anesth Analg; 1998 Apr; 86(4):850-5. PubMed ID: 9539614
[TBL] [Abstract][Full Text] [Related]
19. Six percent hydroxyethyl starch 130/0.4 (Voluven®) versus 5% human serum albumin for volume replacement therapy during elective open-heart surgery in pediatric patients.
Van der Linden P; De Villé A; Hofer A; Heschl M; Gombotz H
Anesthesiology; 2013 Dec; 119(6):1296-309. PubMed ID: 23934169
[TBL] [Abstract][Full Text] [Related]
20. Prospective, randomized, controlled, double-blind, multi-center, multinational study on the safety and efficacy of 6% Hydroxyethyl starch (HES) sOlution versus an Electrolyte solutioN In patients undergoing eleCtive abdominal Surgery: study protocol for the PHOENICS study.
Buhre W; de Korte-de Boer D; de Abreu MG; Scheeren T; Gruenewald M; Hoeft A; Spahn DR; Zarbock A; Daamen S; Westphal M; Brauer U; Dehnhardt T; Schmier S; Baron JF; De Hert S; Gavranović Ž; Cholley B; Vymazal T; Szczeklik W; Bornemann-Cimenti H; Soro Domingo MB; Grintescu I; Jankovic R; Belda J
Trials; 2022 Feb; 23(1):168. PubMed ID: 35193648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
